Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA
ACCESSWIRE•06/08/2026•09:00 ET
0
Whiz Insights
Get started
Create a free account to read the full story.
Create a free account to read the full story.